Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sexual Function Outcomes Following Peri-clitoral PRP (SPARk)

17 novembre 2026 aggiornato da: Medstar Health Research Institute

Sexual Function Outcomes Following Peri-clitoral PRP Added to Anterior Vaginal Wall PRP: A Randomized Controlled Trial

The goal of this clinical trial is to learn if adding platelet-rich plasma (PRP) injections near the clitoris improves sexual function more than PRP injections in the vaginal wall alone. The study includes sexually active adults who were assigned female at birth. PRP is made from a person's own blood. It contains growth factors that may help tissue heal and renew.

The main questions it aims to answer are:

Does adding PRP near the clitoris improve sexual function 6 weeks after treatment, compared with vaginal wall PRP alone? Do any improvements last at 3 and 6 months? How painful are the injections, and what side effects do participants have?

Researchers will compare two groups. All participants will get PRP injected into the front wall of the vagina. One group will also get PRP injected near the clitoris. The other group will get a placebo (sham) injection near the clitoris: the needle goes under the skin, but nothing is injected. Participants will not know which group they are in.

Participants will:

Answer questionnaires about their health and sexual function before treatment. Come to one in-person visit, about 1 hour long. At this visit they will have blood drawn to make the PRP and receive the injections.

Rate their pain shortly after the injections. Complete 3 short online follow-up visits at 6 weeks, 3 months, and 6 months. At these visits they will answer questionnaires about sexual function and side effects.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

**Background and Rationale**

Female sexual dysfunction (FSD) affects approximately 43% of women in the United States, and 23% report associated distress. Non-hormonal treatment options are limited. Platelet-rich plasma (PRP) is an autologous concentrate of platelets. On activation, platelets release growth factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These factors are hypothesized to promote angiogenesis, collagen synthesis, and neural regeneration in target tissues.

The Vaginal Injection of Platelet-Rich Plasma (VIP) trial was a single-blind randomized controlled trial conducted through the MedStar Health Research Institute. Compared with saline injection, anterior vaginal wall PRP produced greater improvement in Female Sexual Function Index (FSFI) total scores at 6 weeks and 6 months. PRP recipients also had higher global impression of improvement and no serious adverse events, although PRP injection was more painful than saline.

Commercial protocols (e.g., the "O-Shot") commonly add peri-clitoral injection to vaginal wall injection. Uncontrolled data that included peri-clitoral injection reported larger FSFI gains than those seen in the VIP trial (Runels et al., 2014; n=11). However, that study did not isolate the peri-clitoral component, and it reported two cases of extreme sexual arousal. Other peri-clitoral data come from studies without adjunctive vaginal wall injection.

The clitoral complex extends well beyond the glans to include the bulbs and crura. It is densely innervated and highly vascular, which makes it a plausible target for regenerative therapy. It is also a site where adverse sensory effects are of particular concern. No randomized data exist on the incremental benefit or risk of peri-clitoral PRP added to anterior vaginal wall PRP. This trial addresses that gap.

**Study Design**

This is a single-site, single-blind (participant-blinded), randomized, sham-controlled, parallel-group superiority trial. Both arms receive anterior vaginal wall PRP, so the design isolates the effect of the peri-clitoral component. Participants are randomized 1:1 using the REDCap randomization module. Unblinded study staff perform the randomization immediately before the procedure. Injecting physicians and study staff are unblinded. Allocation is concealed from participants until study completion, except in emergencies requiring knowledge of treatment assignment.

**Intervention Details**

Participants undergo venipuncture of 40-60 mL whole blood. Samples are labeled with study ID and date and transported within 30 minutes to an on-site centrifuge at MedStar Lafayette Centre. PRP is prepared with the Arthrex Angel system using a 15-minute centrifugation, which yields approximately 2-4 mL of leukocyte-rich PRP. PRP is used within 2 hours of centrifugation and requires no storage. This follows an established institutional orthopedic protocol. Residual blood product is discarded as biohazard waste, and no specimens are banked.

All injections are performed after topical anesthesia by trained, IRB-approved physicians using a 28-32 gauge needle with a superficial technique and retrograde withdrawal:

  • **Anterior vaginal wall (both arms):** Two-thirds of the PRP volume is injected just deep to the epithelium of the distal anterior vaginal wall, approximately 3 cm from the urethral meatus.
  • **Peri-clitoral, active arm:** The remaining one-third (approximately 1 mL) is delivered as two superficial injections of approximately 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum.
  • **Peri-clitoral, sham arm:** The needle is inserted at the same sites without injecting any substance.

Participants are observed for 15 minutes after injection.

**Sample Size**

The sample size was calculated in PASS 2024 (v24.0.6) for a two-sided, two-sample t-test of the difference in baseline-to-6-week change in FSFI total score. Assumptions were α=0.05, 80% power, SD of 5.1 at each time point, and a within-subject correlation of 0.5. The target difference was 4.05 points, the distribution-based FSFI MCID. Published anchor-based estimates are similar. This requires 26 participants per arm. With 10% anticipated attrition, enrollment is 29 per arm (58 total).

**Statistical Analysis**

All tests are two-sided at α=0.05. Benjamini-Hochberg false discovery rate correction is applied to secondary analyses. Missing data are handled by complete-case analysis per outcome.

  • **Primary comparison:** A two-sample t-test of between-arm difference in change scores, reported with a 95% CI.
  • **Responder analyses:** Logistic regression adjusted for baseline FSFI.
  • **Longitudinal and subdomain analyses:** Linear mixed-effects models with treatment, time, treatment×time interaction, and baseline FSFI as fixed effects and a random participant intercept. Estimated marginal means are compared at each time point.
  • **Global impression of improvement:** Cumulative logit mixed-effects models.
  • **Procedural pain:** Summarized descriptively by arm with 95% CIs.
  • **Adverse events:** Compared using Poisson regression with robust standard errors, reported as incidence rate ratios.

**Safety Monitoring**

Safety assessment focuses on outcomes specific to the peri-clitoral site: bleeding, infection, sensory changes (numbness, hypersensitivity), and unexpected or undesired arousal. An independent safety monitor reviews all adverse event data at 50% enrollment. Any serious adverse event is reported to the MHRI IRB, and enrollment is paused pending safety monitor review.

Tipo di studio

Interventistico

Iscrizione (Stimato)

58

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20036
        • Reclutamento
        • MedStar Health at Lafayette Centre
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Adults 18 years of age or older who were assigned female at birth
  • Sexually active, with at least one episode of sexual activity (alone or with a partner) in the past month
  • English speaking
  • Able to complete study questionnaires
  • Willing to undergo blood draw and genital injection procedure

Exclusion Criteria:

  • Pregnant, suspected pregnancy, or breastfeeding/lactating
  • Active infection
  • Autoimmune condition
  • History of pelvic radiation
  • History of pelvic malignancy
  • Current use of anticoagulant medication
  • Prior urogenital platelet-rich plasma injection
  • History of female genital mutilation/cutting
  • Presence of urethrovaginal mesh (including midurethral sling)
  • Chronic or acute pelvic pain preventing pelvic examination
  • Active genital infection

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore fittizio: Anterior Vaginal Wall PRP + Periclitoral Sham

All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive a sham injection into the peri-clitoral sites.

A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle.

Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum.

Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance.

Participants are blinded to peri-clitoral assignment.

Altri nomi:
  • PRP
Sperimentale: Anterior Vaginal Wall PRP + Periclitoral PRP

All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive active PRP injection into the peri-clitoral sites.

A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle.

Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum.

Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance.

Participants are blinded to peri-clitoral assignment.

Altri nomi:
  • PRP

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Female Sexual Function Index Total Score
Lasso di tempo: Baseline and 6 weeks after treatment

Change in total Female Sexual Function Index (FSFI) score from baseline to 6 weeks after treatment, compared between the peri-clitoral PRP and peri-clitoral sham arms. The FSFI is a validated 19-item self-report questionnaire assessing six domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

Baseline and 6 weeks after treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Female Sexual Function Index Total Score at 3 Months
Lasso di tempo: Baseline and 3 months after treatment

Change in total Female Sexual Function Index (FSFI) score from baseline to 3 months after treatment, compared between arms. The FSFI is a validated 19-item self-report questionnaire. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

Baseline and 3 months after treatment
Change in Female Sexual Function Index Total Score at 6 Months
Lasso di tempo: Baseline and 6 months after treatment

Change in total FSFI score from baseline to 6 months after treatment, compared between arms. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

Baseline and 6 months after treatment
Change in Female Sexual Function Index Domain Scores
Lasso di tempo: Baseline, 6 weeks, 3 months, and 6 months after treatment

Change from baseline in each of the six FSFI domain scores, compared between arms. The domains are desire (range 1.2-6.0), arousal (0-6.0), lubrication (0-6.0), orgasm (0-6.0), satisfaction (0.8-6.0), and pain (0-6.0). Higher scores indicate better function.

Baseline, 6 weeks, 3 months, and 6 months after treatment
Proportion of Participants With Clinically Meaningful Improvement
Lasso di tempo: Baseline, 6 weeks, 3 months, and 6 months after treatment

Percentage of participants in each arm whose total FSFI score increases by at least 4.05 points from baseline, the minimal clinically important difference.

Baseline, 6 weeks, 3 months, and 6 months after treatment
Proportion of Participants Above the Sexual Dysfunction Threshold
Lasso di tempo: 6 weeks, 3 months, and 6 months after treatment

Percentage of participants in each arm with a total FSFI score of 26.55 or higher, the validated cutoff for distinguishing women with and without sexual dysfunction.

6 weeks, 3 months, and 6 months after treatment
Patient Global Impression of Improvement
Lasso di tempo: 6 weeks, 3 months, and 6 months after treatment

Participant rating of change in sexual function since treatment on the Patient Global Impression of Improvement (PGI-I), a single-item 7-point scale from 1 (very much better) to 7 (very much worse). Lower scores indicate greater improvement. Compared between arms.

6 weeks, 3 months, and 6 months after treatment
Procedural Pain
Lasso di tempo: Approximately 10-15 minutes after injection on the day of treatment

Pain from the injection procedure, rated on a visual analog scale from 1 (least pain) to 10 (worst pain). Higher scores indicate more pain. Compared between arms.

Approximately 10-15 minutes after injection on the day of treatment
Adverse Events
Lasso di tempo: From treatment through 6 months after treatment

Number and type of adverse events in each arm. These include bleeding, infection, abnormal discharge, worsening or persistent pain, numbness, hypersensitivity, undesired changes in sexual arousal or genital sensation, and serious adverse events.

From treatment through 6 months after treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Alexis Dieter, MD, Medstar Health Research Institute

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 maggio 2028

Date di iscrizione allo studio

Primo inviato

2 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared. Data include sensitive sexual health and demographic information from a small, single-site sample, which poses a meaningful risk of re-identification, and participants were not consented for data sharing beyond the study team.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi